Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution - 2Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- 3'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- 4Instructions to Keep up with Your Traded Teeth for Life span
- 5See the moon shine with Saturn in the southern sky after sunset Dec. 26
- 6 Modest and Strong Tire Brands
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Spots To Go Birdwatching All over the Planet
- Some Americans say they'll go without health insurance as ACA rates spike
- Vote in favor of Your #1 4\u00d74 SUVs
- Trump signs bill allowing whole milk to return to school lunches
- Wedding trip Objections in the US
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Picking the Right Air Purifier for Your Home
